Disease: Pseudoinflammatory fundus dystrophy
- Choriocapillaris Flow Signal Impairment in Sorsby Fundus Dystrophy
- Deglycosylation Increases the Aggregation and Angiogenic Properties of Mutant Tissue Inhibitor of Metalloproteinase 3 Protein: Implications for Sorsby Fundus Dystrophy
- Early-Onset TIMP3-Related Retinopathy Associated With Impaired Signal Peptide
- Evaluating the impact of marketing interventions on sugar-free and sugar-sweetened soft drink sales and sugar purchases in a fast-food restaurant setting
- Extracellular matrix dysfunction in Sorsby patient-derived retinal pigment epithelium
- In vitro stem cell modelling demonstrates a proof-of-concept for excess functional mutant TIMP3 as the cause of Sorsby fundus dystrophy
- Late-Stage Sorsby Fundus Dystrophy Manifesting Severe Vision Loss in the Absence of Choroidal Neovascularization
- LONG-TERM VISUAL ACUITY PRESERVATION IN SORSBY FUNDUS DYSTROPHY WITH CORTICOSTEROID TREATMENT
- Potential CRISPR Base Editing Therapeutic Options in a Sorsby Fundus Dystrophy Patient
- Pseudoinflammatory fundus dystrophy with autosomal recessive inheritance
- Pseudoinflammatory fundus dystrophy: a follow-up study
- Role of FGF and Hyaluronan in Choroidal Neovascularization in Sorsby Fundus Dystrophy
- Sorsby fundus dystrophy (SFD): A narrative review
- Sorsby Fundus Dystrophy Mutation in Tissue Inhibitor of Metalloproteinase 3 (TIMP3) promotes Choroidal Neovascularization via a Fibroblast Growth Factor-dependent Mechanism
- Sorsby fundus dystrophy with polypoidal choroidal vasculopathy: Extending TIMP3 phenotypes
- Sorsby Pseudoinflammatory Fundus Dystrophy
- The N-terminal p.(Ser38Cys) TIMP3 mutation underlying Sorsby fundus dystrophy is a founder mutation disrupting an intramolecular disulfide bond
- Treatment of Sorsby fundus dystrophy with anti-tumor necrosis factor-alpha medication